Abstract
Adding a PI3K inhibitor to anti-estrogen receptor therapy may be a viable treatment option for women with advanced hormone receptor-positive breast cancer that becomes resistant to endocrine therapy, according to findings from the phase III BELLE-2 trial, presented at the 2015 San Antonio Breast Cancer Symposium.
©2016 American Association for Cancer Research.
MeSH terms
-
Aminopyridines / therapeutic use*
-
Antineoplastic Agents, Hormonal / pharmacology
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Clinical Trials, Phase III as Topic
-
Congresses as Topic
-
Disease-Free Survival
-
Drug Resistance, Neoplasm / drug effects
-
Estradiol / analogs & derivatives*
-
Estradiol / pharmacology
-
Estradiol / therapeutic use
-
Female
-
Fulvestrant
-
Humans
-
Morpholines / therapeutic use*
-
Phosphatidylinositol 3-Kinase / genetics
-
Phosphoinositide-3 Kinase Inhibitors
-
Treatment Outcome
Substances
-
Aminopyridines
-
Antineoplastic Agents, Hormonal
-
Morpholines
-
NVP-BKM120
-
Phosphoinositide-3 Kinase Inhibitors
-
Fulvestrant
-
Estradiol
-
Phosphatidylinositol 3-Kinase